Next report date
Report period
Q1 2024
EPS estimate
−0.24USD
Revenue estimate
19.96 MUSD
−1.272USD
−281.27 MUSD
58.12 MUSD
91.60 M
About CureVac N.V.
Sector
CEO
Alexander Zehnder
Headquarters
Tübingen
Website
Employees (FY)
1.17 K
Founded
2020
ISIN
NL0015436031
FIGI
BBG0113J0082
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0A9E is 2.284 USD — it has increased by 0.84% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange CUREVAC NV COM EUR0.12 stocks are traded under the ticker 0A9E.
CUREVAC NV COM EUR0.12 is going to release the next earnings report on May 22, 2024. Keep track of upcoming events with our Earnings Calendar.
0A9E stock is 5.25% volatile and has beta coefficient of 0.55. Check out the list of the most volatile stocks — is CUREVAC NV COM EUR0.12 there?
0A9E earnings for the last quarter are −0.23 USD per share, whereas the estimation was −0.24 USD resulting in a 2.27% surprise. The estimated earnings for the next quarter are −0.22 USD per share. See more details about CUREVAC NV COM EUR0.12 earnings.
CUREVAC NV COM EUR0.12 revenue for the last quarter amounts to 17.44 M USD despite the estimated figure of 17.94 M USD. In the next quarter revenue is expected to reach 42.82 M USD.
Yes, you can track CUREVAC NV COM EUR0.12 financials in yearly and quarterly reports right on TradingView.
0A9E stock has fallen by 7.69% compared to the previous week, the month change is a 25.11% fall, over the last year CUREVAC NV COM EUR0.12 has showed a 68.88% decrease.
0A9E net income for the last quarter is −93.19 M USD, while the quarter before that showed −52.96 M USD of net income which accounts for −75.97% change. Track more CUREVAC NV COM EUR0.12 financial stats to get the full picture.
Today CUREVAC NV COM EUR0.12 has the market capitalization of 521.65 M, it has decreased by 5.07% over the last week.
No, 0A9E doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0A9E shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CUREVAC NV COM EUR0.12 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 1.17 K employees. See our rating of the largest employees — is CUREVAC NV COM EUR0.12 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CUREVAC NV COM EUR0.12 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CUREVAC NV COM EUR0.12 stock shows the sell signal. See more of CUREVAC NV COM EUR0.12 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CUREVAC NV COM EUR0.12 future price: according to them, 0A9E price has a max estimate of 18.06 USD and a min estimate of 2.61 USD. Read a more detailed CUREVAC NV COM EUR0.12 forecast: see what analysts think of CUREVAC NV COM EUR0.12 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CUREVAC NV COM EUR0.12 EBITDA is −275.32 M USD, and current EBITDA margin is −473.93%. See more stats in CUREVAC NV COM EUR0.12 financial statements.